Comment on Merck Reaffirms Commitment to Cubist Deal

Merck Reaffirms Commitment to Cubist Deal

Drug maker Merck is facing criticism that it is overpaying for its planned $8.4 billion purchase of Cubist after a court ruled that the company’s flagship antibiotic could be subject to generic competition.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News